Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and ...

California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB ...

Social proof—seeing peers safely participate—reduces fear and builds trust in clinical trials. Sharing real stories and ...

Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning Amvuttra's new ATTR-CM indication approval against competitors in the category.

The GLP-1 drug market is booming, fueled by their success in treating diabetes and obesity. Yet, this growth has unleashed a torrent of litigation — patent disputes, regulatory battles, and clashes ...

They say the mark of intelligence is making the complex simple. By that standard, navigating early commercialization in the pharmaceutical industry is one of the toughest challenges, especially for ...